Syndax Pharmaceuticals' experimental drug revumenib achieved 23% complete remission in NPM1-mutated acute myeloid leukemia ...

AstraZeneca CEO Pascal Soriot affirms commitment to China despite investigation involving China president Leon Wang and other ...

Pfizer, reportedly working with Goldman Sachs, is considering selling its hospital drugs unit while facing pressure from ...

Merck KGaA's pimicotinib met its primary endpoint in Phase 3 MANEUVER trial for tenosynovial giant cell tumors, showing 54% ...

Mer­ck and As­traZeneca are hop­ing to ex­pand the la­bel of their MEK in­hibitor Kosel­u­go to cer­tain adult pa­tients with ...

Bayer CEO Bill Anderson affirmed plans to manage Xarelto's generic competition decline, as shares hit record low following Q3 ...

AstraZeneca announces $2 billion investment to create 1,000 new US jobs, adding to previous $1.5 billion commitment. The $3.5 ...

Diverge, a startup helping Medicaid members access care, raised $52 million led by Alphabet's GV. The company, launched in ...

AstraZeneca and Daiichi Sankyo withdrew their filing for datopotamab deruxtecan (Dato-DXd) in nonsquamous non-small cell lung ...

No­var­tis will pay $150 mil­lion up­front to Schrödinger, in a pact an­nounced Tues­day to work to­geth­er on sev­er­al ...

Apollo Therapeutics will pay $12M upfront and up to $926M in milestone payments to Sunshine Lake Pharma for worldwide rights (excluding China) to their FGF21/GLP-1 dual receptor agonist ...

Swiss biotech Alentis Therapeutics thinks it can expand the reach of the Claudin family in oncology, and half a dozen new ...